Sort by topic:

The Future of Axial Spondyloarthritis Treatment


Hillary Norton, MD, discusses the unmet needs in the treatment of axial spondyloarthritis and provides community rheumatologists with management advice. 

Transcript

Hillary Norton, MD: There are unmet needs yet in the treatment of axSpA [axial spondyloarthritis] and AS [ankylosing spondylitis] patients. TNF [tumor necrosis factor] inhibitors and IL-17 inhibitors work very well for many of our patients, but we still have cases in which if someone doesn’t respond to 1 of these biologics, the pipeline includes new classes of medications that are coming, and this will provide more options for these patients who don’t respond to the medications we currently have.

I think the main thing to keep in mind for community physicians who are seeing people with back pain is the distinction between mechanical and inflammatory back pain. If somebody comes in under the age of 35 with back pain that has been persistent for more than 3 months, who has night pain, particularly in the second half of the night, and pain that is better with activity and worse with rest, and is responsive to NSAIDs [nonsteroidal anti-inflammatory drugs], these are red flags that this may be treatable inflammatory back pain and a referral to rheumatology is warranted.
 


Episode #1

Axial Spondyloarthritis Defined
Axial Spondyloarthritis Defined

Episode #2

Epidemiology of Axial Spondyloarthritis
Epidemiology of Axial Spondyloarthritis

Episode #3

Accurately Diagnosing Axial Spondyloarthritis
Accurately Diagnosing Axial Spondyloarthritis

Episode #4

Unmet Needs in the Diagnosis of Axial Spondyloarthritis
Unmet Needs in the Diagnosis of Axial Spondyloarthritis

Episode #5

Axial Spondyloarthritis and Quality of Life
Axial Spondyloarthritis and Quality of Life

Episode #6

Establishing Goals of Therapy in Axial Spondyloarthritis
Establishing Goals of Therapy in Axial Spondyloarthritis

Episode #7

Clinical Recommendations: Managing Axial Spondyloarthritis
Clinical Recommendations: Managing Axial Spondyloarthritis

Episode #8

Treating Axial Spondyloarthritis
Treating Axial Spondyloarthritis

Episode #9

Axial Spondyloarthritis: Future Outlook
Axial Spondyloarthritis: Future Outlook

Episode #10

Nonradiographic Versus Radiographic Axial Spondyloarthritis
Nonradiographic Versus Radiographic Axial Spondyloarthritis

Episode #11

The Epidemiology of Axial Spondyloarthritis
The Epidemiology of Axial Spondyloarthritis

Episode #12

Diagnosing Axial Spondyloarthritis
Diagnosing Axial Spondyloarthritis

Episode #13

AxSpa Treatment Goals and Windows of Opportunity
AxSpa Treatment Goals and Windows of Opportunity

Episode #14

AxSpa Treatments: TNF Inhibitors, NSAIDs, and Opioids
AxSpa Treatments: TNF Inhibitors, NSAIDs, and Opioids

Episode #15

The Future of Axial Spondyloarthritis Treatment
The Future of Axial Spondyloarthritis Treatment
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$